Ligand Pharmaceuticals backs Athira Pharmas $90 million funding round

Ligand Pharmaceuticals backs Athira Pharmas $90 million funding round
@Ligand_LGND: Ligand backs Athira Pharma funding

Ligand Pharmaceuticals is making significant financial strides by supporting Athira Pharma through a $90 million private placement financing round. This move aims to bolster the development of lasofoxifene, a promising Phase 3 oncology asset, strengthening Ligand's pharmaceutical pipeline.

The investment highlights Ligand's strategic focus on enriching its oncology portfolio through cutting-edge advancements. Lasofoxifene is attracting attention as it nears pivotal study phases, potentially offering substantial returns and expanding treatment options within the cancer therapy sector.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.